Scope
NICE guideline NG73 covers the diagnosis and management of endometriosis. The source includes recommendations from 2017, some new or amended in 2024, and cross-references to later NICE technology appraisals on GnRH antagonists. It covers: - organisation of care through managed clinical networks linking community, gynaecology and specialist endometriosis services; - information and support; - recognising symptoms and signs, including in young women; - examination and first-line analgesic and hormonal treatment; - ultrasound, MRI and laparoscopic diagnosis, and referral pathways; - treatment according to symptoms rather than stage; - monitoring, surgical management including hysterectomy, and management when fertility is a priority. The guideline states that investigations and referral should run alongside initial drug treatment. It also stresses that normal examination or imaging does not exclude endometriosis.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Organisation of care, information and support
- Establish a managed clinical network for suspected or confirmed endometriosis. It should link community services, gynaecology services and specialist endometriosis centres. These services should provide coordinated care and have processes for prompt diagnosis and treatment, because delay can harm quality of life and allow disease progression. [1]
- Gynaecology services should have access to a gynaecologist with laparoscopic skills in endometriosis. Specialist centres should have access to resources that include a colorectal surgeon and a urologist with an interest in endometriosis, multidisciplinary pain services with pelvic pain expertise, and advanced diagnostic facilities such as radiology and histopathology. [1]
- Assess each person's information and support needs, including fertility wishes. Provide information on diagnosis, the care pathway and referral criteria, and update it throughout care. With the woman's agreement, involve her partner or others important to her. [1]
Recognition and clinical assessment
- Suspect endometriosis, including in those aged 17 and under, when any of the following is present: - chronic pelvic pain (pain lasting 6 months or longer); - dysmenorrhoea affecting daily life; - deep dyspareunia; - cyclical bowel symptoms such as painful defecation; - cyclical urinary symptoms such as haematuria or dysuria; - infertility alongside any of these. [1]
- Ask about endometriosis in first-degree relatives, as it raises likelihood. Tell patients that a pain and symptom diary can help discussions. Recognise that pain experience and expression vary between individuals. [1]
- Offer abdominal and internal vaginal examination to look for masses, reduced organ mobility, posterior fornix nodularity and visible vaginal lesions. If pelvic examination is declined or unsuitable, offer abdominal examination to exclude masses. [1]
Initial pharmacological treatment
- Consider a short first-line trial, for example 3 months, of paracetamol and/or an NSAID for endometriosis-related pain. If relief is inadequate, consider other pain management and referral for further assessment. [1]
- Offer hormonal treatment, such as a combined oral contraceptive or a progestogen, for suspected, confirmed or recurrent disease. This use was off-label for some products at the time the recommendation was made. Explain that hormonal treatment can reduce pain and does not permanently impair later fertility. [1]
Investigation and referral
- Arrange investigations and any referral in parallel with initial drug treatment. Offer transvaginal ultrasound, organised by general practice, to everyone with suspected endometriosis, even if examination is normal. Its purpose is to detect endometriomas and deep disease and to identify or rule out other pathology. [1]
- If transvaginal scanning is declined or unsuitable, consider transabdominal pelvic ultrasound. Normal examination and ultrasound do not exclude endometriosis, and referral may still be needed. [1]
- Refer people with symptoms of, or confirmed, endometriosis to gynaecology for further investigation and management if: - initial treatment is ineffective, not tolerated or contraindicated; - symptoms impair daily living; - symptoms are persistent or recurrent; - pelvic signs are present without suspected deep disease. [1]
- Refer to a specialist endometriosis centre for suspected or confirmed endometrioma, deep disease including that involving bowel, bladder or ureter, or extrapelvic disease. Refer those aged 17 and under to paediatric and adolescent gynaecology or a specialist centre. [1]
- Serum CA125 should not be used for diagnosis. [1]
- Consider specialist transvaginal ultrasound or pelvic MRI to diagnose and map deep endometriosis, including before operative laparoscopy. These scans should be planned and interpreted by a professional with specialist gynaecological imaging expertise. [1]
- Consider diagnostic laparoscopy even after normal imaging. A suitably trained gynaecologist should systematically inspect the pelvis and record findings, including intra-operative imaging. During diagnostic laparoscopy, consider biopsy of suspected endometriosis to confirm the diagnosis, noting that negative histology does not exclude endometriosis. Also consider biopsy to exclude malignancy when an endometrioma is treated but not excised. [1]
- If a properly documented systematic laparoscopy is normal, explain that endometriosis is unlikely and offer alternative symptom management. [1]
Surgical management, monitoring and other treatments
- Base treatment on symptoms, preferences and priorities rather than disease stage. Document the appearance and site of endometriosis when diagnosed. Perform surgery laparoscopically unless contraindicated, recording results with intra-operative imaging. [1]
- At diagnostic laparoscopy, consider treating peritoneal disease not involving bowel, bladder or ureter, and uncomplicated ovarian endometriomas, if present. Before surgery for deep disease involving these organs, consider 3 months of GnRH agonist as an adjunct. This was off-label for some agents when recommended. [1]
- Consider excision over ablation for endometriomas, weighing fertility wishes and ovarian reserve. After laparoscopic excision or ablation, consider hormonal treatment, such as a combined oral contraceptive, to prolong benefit and control symptoms. [1]
- When hysterectomy is indicated, for example for adenomyosis or refractory heavy menstrual bleeding, excise all visible lesions at the same time. Perform it laparoscopically unless contraindicated. With women considering hysterectomy, discuss recurrence, concurrent oophorectomy, and the risks and benefits of HRT after oophorectomy. [1]
- Consider outpatient follow-up, with or without examination and imaging, for confirmed endometriosis with deep endometriosis involving the bowel, bladder or ureter, or with 1 or more endometrioma larger than 3 cm. This applies particularly to people who choose not to have surgery. [1]
- Advise that evidence does not support traditional Chinese medicine, Chinese herbal medicines or supplements for endometriosis. [1]
Management when fertility is a priority
- Offer the following, because each improves the chance of spontaneous pregnancy: - excision or ablation plus adhesiolysis for disease not involving bowel, bladder or ureter; - for endometriomas, laparoscopic cystectomy with cyst-wall excision, or drainage and ablation. For endometriomas, take into account the possible impact on ovarian reserve, and that drainage and ablation may preserve it more than cystectomy. [1]
- For deep endometriosis in people trying to conceive, discuss the benefits and risks of laparoscopic surgery. Topics may include its effect on future pregnancy chances and alternatives to surgery. Do not offer hormonal treatment, alone or with surgery, to people trying to conceive, because it does not improve spontaneous pregnancy rates. [1]
Limitations and use
- The source contains clinical recommendation text only. Research recommendations, rationale and impact sections, evidence reviews, update history and committee information were not available.
- Flowcharts and visual algorithms were available only as alternative text and were not reviewed.
- GnRH antagonist options (linzagolix with add-back therapy and relugolix–estradiol–norethisterone) are cross-referenced to separate NICE technology appraisals. Their eligibility criteria are not included here.
- Neuropathic pain treatment, fertility investigations and assisted reproduction, ovarian reserve testing, menopause/HRT and patient experience are deferred to other NICE guidelines that were not supplied.
- Most recommendations date from 2017, with some new or amended in 2024. NICE notes the guideline does not consistently use inclusive language, because evidence for some groups was limited or not reviewed.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Endometriosis: diagnosis and management
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 6 September 2017
- Publisher’s latest update
- 11 November 2024
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.